Table 1.
Clinical characteristics of CD and UC patients according to presence of TPL2 risk alleles.
| Genotype (CD) | AA | AG | GG |
|---|---|---|---|
| Number (%) | 210 (17.5) | 562 (47) | 425 (35.5) |
| CD patients | AA | AG/GG | p-value (Wilcoxon) |
| Age at Diagnosis | |||
| Median, q25–q75, | 23, 17–31, | 23.5, 17–34, | 0.657 |
| min–max | 5–73 | 1–81 | |
| Genotype: | AA | AG/GG | p-value (chi2) |
| Gender |
|
|
|
| Men | 110 (52.4) | 491 (49.7) | 0.488 |
| Women | 100 (47.6) | 496 (50.3) | |
| Peripheral arthritis | |||
| Yes | 21 (14.8) | 232 (23.5) | 0.005 |
| No | 179 (85.2) | 755 (76.5) | |
| Uveitis/Iritis | |||
| Yes | 1 (0.5) | 10 (1) | 0.459 |
| No | 209 (99.5) | 977 (99) | |
| Pyoderma gangrenosum | |||
| Yes | 1 (0.5) | 5 (0.5) | 0.955 |
| No | 209 (99.5) | 982 (99.5) | |
| Erythema nodosum | |||
| Yes | 0 | 8 (0.8) | 0.191 |
| No | 210 (100) | 979 (99.2) | |
| Aphtous oral ulcers | |||
| Yes | 6 (2.9) | 27 (2.7) | 0.922 |
| No | 204 (97.1) | 960 (97.3) | |
| Ankylosing spondylitis | |||
| Yes | 6 (2.9) | 14 (1.4) | 0.140 |
| No | 204 (97.1) | 973 (98.6) | |
| Prim. scler. cholangitis | |||
| Yes | 0 | 5 (0.5) | 0.301 |
| No | 210 (100) | 982 (99.5) | |
| Other | |||
| Yes | 2 (0.9) | 10 (1) | 0.936 |
| No | 208 (99.1) | 977 (99) | |
| Summary of Extraintestinal manifestations | |||
| Yes | 40 (19) | 258 (26.1) | 0.031 |
| No | 170 (81) | 729 (73.9) | |
| Genotype (UC): | AA | AG | GG |
| Number (%) | 173 (18.3) | 449 (47.4) | 326 (34.3) |
| UC patients | AA | AG or GG | p-value (Wilcoxon) |
| Age at Diagnosis | |||
| Median, q25–q75, | 26, 19–37, | 27, 17–36, | 0.404 |
| min–max | 3–75 | 2–79 | |
| Number (%) | AA | AG or GG | p-value (chi2) |
| Gender | |||
| Men | 81 (46.8) | 426 (55) | 0.052 |
| Women | 92 (53.2) | 349 (45) | |
| Surgery | |||
| Yes | 7 (4) | 11 (1.4) | 0.022 |
| No | 166 (96) | 764 (98.6) |